2,4-Dihydroxy-3-(3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl)-6-propylbenzoic acid

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2,4-Dihydroxy-3-(3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl)-6-propylbenzoic acid
• 化学式: C₂₀H₂₆O₄
• 分子量: 330.4
• InChiKey: CZXWOKHVLNYAHI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.5
• 重原子数：
  24
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  77.8
• 氢给体数：
  3
• 氢受体数：
  4

文献信息

• [EN] CANNABINOID DERIVATIVES<br/>[FR] DÉRIVÉS DE CANNABINOÏDES
  申请人：CANOPY GROWTH CORP

  公开号：WO2021062557A1

  公开（公告）日：2021-04-08

  This disclosure relates generally to cannabinoid derivatives having the formula (I), wherein R4 is hydrogen, -C(Q1)N(R4a)(R4b) or -C(R4J)(R4k)N(R4e)C(0)R4f, R6 is hydrogen, -C(Q2)N(R6a)(R6b) or -C(R6J)(R6k)N(R6e)C(0)R6f, provided that R6 is not hydrogen when R4 is hydrogen. Pharmaceutical compositions for the prevention or treatment of a disease associated with a cannabinoid receptor (such as CB1 or CB2) in a subject in need thereof, and methods of using the cannabinoid derivatives are also described.

  本公开涉及一般具有式（I）的大麻素衍生物，其中R4为氢、-C(Q1)N(R4a)(R4b)或-C(R4J)(R4k)N(R4e)C(0)R4f，R6为氢、-C(Q2)N(R6a)(R6b)或-C(R6J)(R6k)N(R6e)C(0)R6f，但当R4为氢时，R6不是氢。还描述了用于预防或治疗与大麻素受体（如CB1或CB2）有关的疾病的药物组合物，以及使用大麻素衍生物的方法。
• USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY
  申请人：GW Research Limited

  公开号：EP3735964A1

  公开（公告）日：2020-11-11

  The present disclosure relates to the use of cannabidiol (CBD) for the treatment of atonic seizures. In particular the CBD appears particularly effective in reducing atonic seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; Aicardi syndrome; CDKL5 and Dup15q in comparison to other seizure types. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).

  本公开涉及使用大麻二酚（CBD）治疗失张力发作。尤其是大麻二酚在减少失张力癫痫发作方面似乎特别有效，这些患者的病因包括Lennox-Gastaut 综合征；结节性硬化综合征；Dravet 综合征；Doose 综合征；Aicardi 综合征；CDKL5 和 Dup15q。本公开进一步涉及 CBD 与一种或多种抗癫痫药物 (AED) 的联合使用。
• Prenyltransferase variants with increased thermostability
  申请人：INVIZYNE TECHNOLOGIES, INC.

  公开号：US11518983B1

  公开（公告）日：2022-12-06

  The present disclosure relates to recombinant prenyltransferase enzymes with increased thermostability and activity and the use of these enzymes in compositions and methods for biosynthesis involving prenylation reactions, including compositions and methods for the preparation of cannabinoids.

  本公开涉及具有更高热稳定性和活性的重组炔基转移酶，以及这些酶在涉及炔基 化反应的生物合成的组合物和方法中的用途，包括制备大麻素的组合物和方法。
• USE OF CANNABIDIOL IN THE TREATMENT OF NOCTURNAL SNORING IN DOOSE SYNDROME
  申请人：GW Research Limited

  公开号：EP3206680B1

  公开（公告）日：2021-04-21
• USE OF CANNABINOIDS IN THE TREATMENT OF ATONIC SEIZURES IN LENNOX-GASTAUT SYNDROME
  申请人：GW Research Limited

  公开号：EP3206716B1

  公开（公告）日：2020-07-29